Brussels, 01 July 2002
At the request of the European Commission, Enterprise DG, the Pharmaceuticals Unit, the EMEA and its Scientific Committee, the Committee for Proprietary Medicinal Products (CPMP) produced a guidance document Note for guidance on the development of vaccinia virus based vaccines against smallpox. This Note for Guidance will be updated as further experience is gained in the development and manufacture of second generation smallpox vaccines.
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to THE’s university and college rankings analysis
Already registered or a current subscriber? Login